Last reviewed · How we verify

NCT06928818

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Recruiting now Last updated 17 April 2025
What this trial tests

trial in Cancer of Breast in 100 participants. Currently enrolling.

Timeline
26 February 2025
Primary endpoint
30 September 2028
30 September 2029

Quick facts

Lead sponsorSeoul National University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date26 February 2025
Primary completion30 September 2028
Estimated completion30 September 2029
Sites1 location across South Korea

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

19 and older, any sex, with Cancer of Breast or Trastuzumab Emtansine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer of Breast

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06928818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing